A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 678 participants.
Also called NCT01381900
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 678 participants
- Registry
-
NCT01381900
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, Malaysia, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT01381900. Randomized; double masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-11 (actual). Results posted on 2014-01-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Canagliflozin 100mg
- Intervention (Drug)
- Canagliflozin 300mg
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulphonylurea
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01381900- Content hash
77edd8eefb6bc5b950a877de5a0e41b903d440e3805cbf21071125ae3e059eb8